Grunenthal Logo

External Link

You are now leaving the Grünenthal website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites.

Title
Description
Trial IDAV001
CompoundCapsaicin 8%
Trials sponsorAveritas Pharma, Inc
Trial phase3
Brief titleComparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery (RISE)
IndicationNeuropathic pain
UTNU1111-1272-1340
CTG IDNCT04967664
CTIS ID (former EudraCT)2024-514934-19-00
Trial statusCompleted
FPIJuly 13, 2021
LPOAugust 28, 2025
CountriesUnited States of America, United Kingdom, France, Poland, Spain, Netherlands
GenderAll
Age>= 18 years of age
ResultsNo
Pubmed
Documents